Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target refers to the transiently exposed single-stranded DNA (ssDNA) segment of the Fukutin-related protein (FKRP) gene created during the formation of an R-loop by the Staphylococcus aureus Cas9 (SaCas9) protein (Ran et al., 2015, Nature). In the context of CRISPR-based genome editing, specifically base editing, SaCas9 uses a guide RNA to locate a specific protospacer sequence within the FKRP gene. Upon binding, the DNA double helix is unwound, and the non-target strand is displaced as ssDNA, making it accessible to tethered effector enzymes such as deaminases (Komor et al., 2016, Nature). This specific editing window is the site where chemical modifications, such as the conversion of cytosine to uracil or adenine to inosine, occur to correct pathogenic mutations. Mutations in the FKRP gene are primarily responsible for Limb-girdle muscular dystrophy type 2I (LGMD2I), characterized by progressive muscle wasting due to defective glycosylation of alpha-dystroglycan (Brockington et al., 2001, Am J Hum Genet). By targeting this ssDNA intermediate, base editors can precisely rewrite the genetic code without inducing double-strand breaks, offering a potential therapeutic pathway for muscular dystrophies. The interaction between the base editor and this ssDNA substrate is highly dependent on the Protospacer Adjacent Motif (PAM) and the length of the guide RNA. Therapeutic strategies focusing on this target aim to restore functional FKRP protein expression in muscle tissues.
Targeted nucleotide deamination (A-to-G or C-to-T transition) within the displaced single-stranded DNA window of the R-loop structure.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Single-stranded DNA within the Staphylococcus aureus Cas9 R-loop at the Fukutin-related protein protospacer (ssDNA in SaCas9-FKRP R-loop).